Cardioprotective effects of semaglutide

The glucagon-like peptide-1 receptor agonist semaglutide may reduce the risk of major adverse cardiovascular events through adiposity measurement reductions in patients with overweight or obesity.

In a study published in The Lancet, investigators conducted a prespecified analysis of the SELECT trial involving more than 17,000 patients aged 45 years and older with a body mass index of 27 kilograms per square meter or greater who were randomly assigned to receive either semaglutide or placebo once weekly.

After a follow-up of 20 weeks, the investigators found that greater decreases in waist circumference among the patients in the semaglutide group were associated with a lower subsequent risk of major adverse cardiovascular events, whereas no linear trend linked weight loss to lower cardiovascular risk.

The findings suggested that waist circumference could partially mediate the cardioprotective effects of semaglutide.

Read more: The Lancet

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.